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CXCR4 is a target of growing interest for the development of new therapeutic drugs and imaging agents
as its role in multiple disease states has been demonstrated. AMD3100, a CXCR4 chemokine receptor
antagonist that is in current clinical use as a haematopoietic stem cell mobilising drug, has been widely
studied for its anti-HIV properties, potential to inhibit metastatic spread of certain cancers and, more
recently, its ability to chelate radiometals for nuclear imaging. In this study, AMD3100 is functionalised on
the phenyl moiety to investigate the influence of the structural modification on the anti-HIV-1 properties
and receptor affinity in competition with anti-CXCR4 monoclonal antibodies and the natural ligand for
CXCR4, CXCL12. The effect of complexation of nickel(II) in the cyclam cavities has been investigated. Two
amino derivatives were obtained and are suitable intermediates for conjugation reactions to obtain
CXCR4 molecular imaging agents. A fluorescent probe (BODIPY) and a precursor for 18F (positron emit-
ting isotope) radiolabelling were conjugated to validate this route to new CXCR4 imaging agents.
Introduction
The CXCR4 chemokine receptor is a seven transmembrane
helix protein, and member of the G-protein-coupled receptor
(GPCR) superfamily.1 It has only one naturally occurring
endogenous ligand known as SDF-1 or CXCL12.2 Together
with its natural ligand, CXCR4 is a central part of the signal-
ling system in the human body that results in a variety of
normal physiological responses, such as chemotaxis, cell survi-
val and proliferation, intracellular calcium flux, and gene tran-
scription. However CXCR4 is also involved in the pathogeneses
of a wide range of diseases.3 Malignant cells from at least 23
different types of cancer express the chemokine receptor
CXCR4 and respond to its ligand CXCL12.4 Furthermore,
CXCR4 is a co-receptor for T-cell tropic strains of human
immunodeficiency virus-1 (HIV-1) and allows fusion and entry
of the virus into human white blood cells.5 Hence, CXCR4 is a
target of growing interest for the development of anti-HIV
drugs and in the field of diagnostic oncology. Clinically
AMD3100 is used in combination with G-CSF (granulocyte
colony stimulating factor) to mobilise haematopoietic stem
cells and allow harvesting.
Inhibition of the CXCR4-CXCL12 signalling was investi-
gated as a therapeutic strategy using antagonists of the natural
ligand. Several CXCR4-binding agents, including antibodies
and peptide-based antagonists have been developed.6 In the
search for new anti-HIV agents, bicyclam compounds were dis-
covered as CXCR4 antagonists with potent and selective anti-
HIV activities.7 These molecules consist of two 14-member tetra-
aza macrocyclic rings, linked either by an aliphatic bridge or
an aromatic bridge such as AMD3100. The latter, unlike many
other existing HIV drugs that target the virus after it has
infected a healthy cell, blocks the virus from entering the cell,
inhibiting the replication of both HIV-1 and HIV-2.8 AMD3100
binds to the CXCR4 chemokine receptor mainly via electro-
static interaction between the positively charged protonated
amino nitrogens of the cyclam moieties and the negatively
charged carboxylates of the aspartate and glutamate residues
of the receptor.9 AMD3100 has also been demonstrated to be a
ligand for another chemokine receptor, CXCR7. In contrast to
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its antagonistic effect blocking the CXCR4/CXCL12 interaction,
AMD3100 positively modulates CXCL12 effects on binding to
CXCR7, it is therefore qualified as an allosteric agonist of
CXCR7.10 AMD3100 was clinically tested as an anti-HIV drug
but the trial was discontinued in favour of an orally available
CXCR4 antagonist.11 Nevertheless, AMD3100 demonstrated a
great potential in hematopoietic stem cell mobilisation and is
now approved by the U.S. Food and Drug Administration for use
in non-Hodgkin’s lymphoma and multiple myeloma patients.12
With the aim of optimising the anti-HIV activity of bis-aza-
macrocycles, many parameters of AMD3100 have been studied
to determine the modifications that can be tolerated whilst
maintaining high CXCR4 receptor affinity. Analogues were syn-
thesised either with a different linker, a macrocycle ring size
varying from 12 to 16 ring members,13 the introduction of one
or more heteroatoms in the macrocycle ring or replacement of
one amino group by a heteroaromatic, all analogues resulting
in a reduced anti-HIV potency (Fig. 1).14
Because of the preorganisation and the flexibility of their
macrocyclic framework, macrocyclic polyamines such as
cyclam, are known to bind to metal ions and form highly
stable metal complexes. Complexes of AMD3100 with metal
cations were prepared and the incorporation of ZnII, NiII and
CuII led to the enhancement of the binding affinity to CXCR4
receptor and a higher anti-HIV activity in most cases. The
nickel(II) complex of AMD3100 in solution can adopt the
folded (cis-V) and planar (trans-III) configuration, rearranging
to give the cis-V compound on binding to the protein aspartate
residues.15 Studies with AMD3100 analogues complexes with
configurationally restricted macrocycles, where ethyl bridges
link adjacent and non-adjacent nitrogen atoms to give respect-
ively side and cross bridged cyclams, demonstrated that the
rigidification of the cyclic scaffold may be a route toward the
optimisation of the interactions of the antagonist with the
receptor.16 Additionally, as metal ion incorporation was shown
to enhance the affinity of AMD3100 for its receptor, the ligand
was used for direct radiolabelling with 62Zn, 64Cu, 67Ga and
99mTc, resulting in tracers suitable for positron emission tom-
ography (PET) and single-photon emission computed tomogra-
phy (SPECT) to image CXCR4 expression in human cancer
xenografts in mice.17
Only two examples of optical CXCR4 imaging agents based
on cyclam structures have been studied despite the advantages
of optical imaging. A rhodamine conjugated to a reinforced
cyclam competes with anti-CXCR4 antibodies during binding
competition when labelled with copper(II)18 and a fluorescent
AMD3100 analogue with an anthracenyl moiety used as a
spacer shows a significant reduction of the affinity prob-
ably due to the lipophilic character of the anthracenyl group.19
In this study, new CXCR4 antagonists are investigated as
potent anti-HIV agents and platforms for conjugation in mole-
cular imaging agent design. The syntheses of new AMD3100
analogues functionalised on the phenyl moiety by an ester or
an ethylenediamine moiety are discussed and we report the
influence of the functionalisation on the affinity towards the
CXCR4 chemokine receptor and antiviral potency against an
X4 HIV-1 strain. Metal complex formation with nickel(II) and
the influence on the binding and antiviral potency will also be
presented. Ni2+ was chosen because its incorporation in the
biscyclam AMD3100 enhances the binding to the chemokine
receptor CXCR4 by 50-fold. This is the highest affinity obtained
by incorporation of a transition metal.22 Finally, the functiona-
lisation on the phenyl spacer allowed the introduction of an
imaging component, i.e. optical probe or PET imaging agent
Fig. 1 AMD3100 and derivatives studied for their anti-HIV activities and CXCR4 affinities.
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precursor, confirming the versatility of the modified AMD3100
derivatives.
Results and discussion
Synthetic procedures
Several synthetic routes to produce AMD3100 are reported in the
literature.20 A cyclam ring protected with tosyl, mesityl, diethyl-
phosphoramidate (Dep) or tert-butoxycarbonyle (Boc) groups is
used as a starting material. Indeed, the best synthetic approach
for bridging two macrocyclic units is to use a triprotected tetra-
azamacrocycle, in order to avoid the formation of polymers. Boc
protecting groups were chosen as they can be easily removed by
acidic treatment. The reaction of the protected macrocycle with
α,α-dibromo-p-xylene and the deprotection in acidic conditions
give access to AMD3100 in two steps (Scheme 1).
To investigate the influence of a functionalisation of the
phenyl moiety on AMD3100 properties, we considered the syn-
thesis of a p-dibromoxylyl spacer substituted with an ester
group. The precursor is obtained in two steps (Scheme 2) start-
ing from a commercially available product, 2,5-dimethylben-
zoic acid.21 Esterification with methanol using sulfuric acid as
a catalyst yields compound 1 in 92% yield. 2 is then prepared
through NBS-based bis-bromination of the aryl methyl groups
of 1.
AMD3100 derivative 3 is obtained in 82% yield, after con-
densation of two equivalents of tris(Boc)cyclam on compound
2 in the presence of a base (Scheme 3). Nucleophilic attack of
ethylenediamine on the ester function gives access to 4 after 6
days at 60 °C. Compounds 3 and 4 are then deprotected in
acidic condition to form respectively 5 and 6 in good yields.
As it has been shown that the incorporation of Ni2+ in the
biscyclam AMD3100 enhances the binding to the chemokine
Scheme 1 General synthesis of AMD3100.
Scheme 2 Synthesis of a dibromo aromatic spacer bearing an ester group.
Scheme 3 Synthesis of new AMD3100 analogues functionalised with an ester and an ethylenediamine group.
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receptor by 50-fold,22 we investigated the metal complex for-
mation of our analogues. Additionally, Ni2+-cyclam complexes
are known to be particularly inert due to their stability con-
stants (log K) indicative of high thermodynamic stability
(19.9–20.3)23 and their slow kinetics of dissociation.24 The
complexes persist almost indefinitely even in strong acidic
solutions and the only reported method to remove Ni2+ from
cyclam involves cyanide at high temperature.
Thus, after deprotonation of 5 and 6 with NaOH (16 M) and
extraction with chloroform, two equivalents of Ni(NO3)2·6H2O
were added to obtain the corresponding Ni2+ complexes
(Scheme 4). Purification by reverse phase chromatography to
remove any trace of free nickel(II) was performed to obtain 7
and 8 in 18% and 39% yield respectively. Yields are low in
these cases due to the purification process. In order to investi-
gate if ethylenediamine pendant arm coordinates one of the
nickel atoms in compound 8, UV-Visible absorption spectra
was recorded in PBS at room temperature (see ESI†). The latter
shows a band at 460 cm−1, characteristic of a low-spin NiII tet-
ramine complex. The amino pendant arm is therefore not
involved in the coordination sphere of nickel.25
Biological assays: antibody competition, calcium signalling
and anti-HIV activity
Cellular binding assays of our AMD3100 analogues to the
CXCR4 receptor were investigated in a competition assay with
an anti-CXCR4 monoclonal antibody (mAb) (12G5 conjugated
to Phycoerythrin). A T-lymphocyte cell line (Jurkat) that
expresses high levels of the CXCR4 receptor was used and the
binding of compounds 5, 6, 7 and 8 to the cells are analysed
by flow cytometry. The binding assay is carried out by satu-
ration of the cells’ receptors with a high concentration of ana-
logues (ca. 20 μM). After incubating with a saturating
concentration of the antagonist, cells are washed to remove
the excess of unbound compound and the specific fluorescent
antibody is introduced. After a second incubation, cells are
washed to remove the excess of antibody and compound dis-
placed by the antibody. Then, cells are analysed by flow cyto-
metry. The Mean Fluorescent Intensity (MFI) is used as a
measure of binding and a quantitative way of calculating the
inhibition percentage of mAb binding. AMD3100 is used as a
reference compound. The non-metallated ligands 5 and 6 both
show a significant decrease in the inhibition percentage com-
pared to AMD3100 with 45% and 46% respectively (Table 1)
(Fig. 2). Incorporation of a metal ion into the macrocyclic rings
of AMD3100 analogues increases binding affinity to CXCR4,
complexes 7 and 8 show higher inhibition percentages, 73%
and 84% respectively, than the non-metallated ligands
(Table 1) (Fig. 2). This is in agreement with Bridger and co-
workers studies.22 A mutational analysis of the CXCR4 binding
site for AMD3100 has identified amino acid Asp171 and Asp262
as key residues involved in the binding to the CXCR4 recep-
tor.11 The carboxylate groups of the receptor residues form
three (one strong, one intermediate and one weak) hydrogen
bonds with protonated cyclam of AMD3100. It was later deter-
mined that the increased binding affinity of the metal ion sub-
stituted AMD3100 is obtained through enhanced interaction of
one of the cyclam ring systems with carboxylate group of
Asp262.22 With metal complexes, coordination of the carboxy-
late oxygens to the metal centre can occur while one weaker
hydrogen bond to a nitrogen atom in the cyclam ring remains.
Coordination interactions are stronger interactions than hydro-
Scheme 4 Nickel(II) complex formation of the AMD3100 analogues.
Table 1 Inhibition of anti-CXCR4 mAb (clone 12G5) binding to CXCR4+
jurkat cells
Compound Control MFIa
Inhibition
percentage
Negative 344.67
5 708.57 45%
6 704.29 46%
7 524.78 73%
8 451.59 84%
AMD3100 413.90 90%
Positive 1005.00
aMean fluorescent intensity used to calculate the amount of antibody
bound to CXCR4.
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gen bonding. Hence they are thought to be the dominant
interactions for metal complexes. Complexes 7 and 8 should
have stronger interactions with the CXCR4 receptor as aspar-
tate residue coordinates nickel(II), resulting in higher inhi-
bition percentages compared to their unmetalated ligands 5
and 6. Even if the functionalisation of our AMD3100 analogues
disrupted the affinity towards CXCR4, the incorporation of
nickel(II) in the cyclam cavities has a positive effect resulting in
inhibition percentages close to those observed for the refer-
ence compound AMD3100. If we compare the different functio-
nalisations of the complexes 7 and 8, the ethylenediamine
analogue has a slightly higher inhibition percentage, which
may be due to more flexible pendant arm that can form hydro-
gen bonds more easily.
Further biological characterisation was carried out to deter-
mine the impact of the antagonism of the receptor in signal-
ling processes and the use of the receptor for viral cell entry.
Prevention of signal transduction by the natural ligand is a
useful indicator of cellular targeting and would inhibit acti-
vation of cell recruitment. Signal inhibition was validated by
measurement of the intracellular calcium concentration
increase, which is a downstream effect of CXCR4 receptor acti-
vation by its specific chemokine ligand CXCL12.26 AMD3100
and the copper(II) complex of AMD3100 were included as con-
trols, see Table 1. The anti-HIV assay was used to co-validate
the signalling data, as this is a well-established assay, which
provides further information on the antagonist characteristics.
The anti-HIV-1 (X4 HIV-1 NL4.3) activity of these compounds
was determined in CD4+CXCR4+ human T cells using the well-
documented HIV-1 infection assay (see Table 2).27
As already mentioned, the chelator units would be expected
to interact with aspartate residues on the CXCR4 chemokine
receptor surface via H-bonding and electrostatic interactions
and the metal complexes would form coordinate bonds.22 In
the signalling assay we can compare compounds 5 and 7
showing in this case that the coordination of nickel(II) does
not increase the affinity of our compounds for CXCR4 as was
observed for the same compounds in the flow cytometry study.
This result correlates with the anti-HIV infection assay
although both still demonstrate sub-µM values. Compounds 6
and 8 show increased potency of the nickel(II) complex in both
calcium signalling and antiviral assays, which is consistent
with antibody competition assay. With an IC50 of 16 nM, 8
presents a higher potency, compared to both AMD3100 and its
copper(II) complex which both have IC50 values >100 nM. The
presence of the appended amino group may be responsible for
this bonding impact as it will be an effective hydrogen bond
donor for interaction with the aspartate/glutamate rich surface
of the CXCR4 receptor.
Overall, although the AMD3100 type structure has been
modified by the introduction of functional groups on the
phenyl moiety, compounds 6 and 8 can be considered as
highly effective CXCR4 antagonists and we can now consider
the introduction of a probe component for molecular imaging
into these structures.
Towards molecular imaging: introduction of an imaging probe
component
Efficient syntheses towards functionalised AMD3100 were
developed whilst maintaining strong anti-HIV potency and
CXCR4 affinity. Both amine analogues 6 and 8 can be used to
conjugate the AMD3100 moiety to an imaging probe as the
primary amine enables coupling reactions with carboxylic
acid, active ester or anhydride. Two different imaging probe
components were attached, a fluorescent moiety and a PET
isotope radiolabelling precursor. The main advantage for PET
imaging here is to introduce the radiolabelling site by
AMD3100 functionalisation rather than using the cyclam
Fig. 2 Flow cytometric histogram plots for the binding of 12G5 mAb in competition with compound 5 (light green) and 6 (dark green) (A) and with
compounds 7 (light blue) and 8 (dark blue) (B). Negative control (purple), positive control (red) and binding of 12G5 mAb in competition with
AMD3100 (orange) are shown.
Table 2 Anti-HIV X4 activity and inhibition of CXCL12-induced calcium
signalling (in µM)
Compound
Anti-HIV-1
(EC50)
a
Ca2+ flux
CXCR4 (IC50)
b
AMD3100 0.011 0.120
Cu2AMD3100 0.062 0.113
5 0.150 0.340
6 0.295 0.929
7 0.710 1.20
8 0.095 0.016
10 0.845 —
11 4.50 —
12 0.800 —
a EC50 is the effective concentration (in µM) to reduce the cytopathic
effect of the CXCR4-using (X4) HIV-1 strain NL4.3 by 50% in MT-4
cells. b IC50 is the inhibitory concentration of the compound (in µM)
required to inhibit 50% of the CXCL-12 (SDF-1) induced Ca2+
signalling in the CXCR4-transfected U87 cell line.
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cavity to chelate a radiometal as it has already been described
and shows low in vivo stability.17 Cyclam can form complexes
that are thermodynamically stable in vitro but it has been
shown that transchelation of the radiometal to ceruloplasmin
and ultimately superoxide dismutase (SOD) can occur in vivo
in the case of 64Cu,28 resulting in accumulation of the radio-
isotope in the blood and liver.17c
Introduction of a BODIPY dye
Amongst the options for fluorescent imaging components,
borodipyrromethane type dyes (4,4-difluoro-4-borata-3a-azonia-
4a-aza-s-indacene, abbreviation BODIPY®) exhibit high stabi-
lity, high extinction coefficients, sharp emission bands and
high quantum yields.29 Additionally, BODIPYs emission can
be shifted to the red-NIR region by extending the π-conjugation
of the central core30 and water soluble dyes can be obtained by
addition of sulfonic acid moieties31 or coupling to an aza-
macrocycle.32 With all of these attractive properties, BODIPYs
appear to be an excellent choice as an optical imaging com-
ponent and a BODIPY carrying an activated ester was prepared
to couple to the amine AMD3100 analogue 6.
Starting from BODIPY-acid, the corresponding N-hydroxy-
succinimidyl ester was obtained upon reaction with NHS in
the presence of EDCI in dichloromethane at room temperature
in 70% yield (Scheme 5).33 The subsequent coupling of the
activated ester with 6 yields 10 in a 65% yield after purification
by column chromatography. Compound 10 was labelled with
Ni2+ and Zn2+ by adding two equivalents of appropriate metal
salts. It has to be noted that, in this case, the zinc complex was
also synthesised, in order to study the influence of the metal
on the fluorescence of the compound. Moreover, Zn2+ also
strongly increases the affinity of AMD3100 for the CXCR4
receptor.22 Both complexes 11 and 12 were isolated in almost
quantitative yield. One important point is that these BODIPY-
AMD3100 analogues are water-soluble without the require-
ment for any solubilising agent (such as DMSO), which is
crucial for biological applications such as molecular imaging.
Indeed, one main drawback for the use of BODIPY dyes in
medical imaging is their very poor solubility in water. It is still
currently challenging to introduce, in a simple synthetic
manner, solubilising groups for biological applications.
Anti-HIV assays were carried out with compounds 10, 11
and 12. These experiments showed that the introduction of the
fluorescent probe induced a reduction of the anti-HIV activity,
although 10 and 12 still maintained sub-µM activity levels, see
Table 2. It was interesting to note that the nickel(II) complex
(11) was again less active than the metal-free chelator 10. This
suggests that the geometric preferences of the nickel(II) ion on
binding to CXCR4 protein aspartate/glutamate side chains
may be disrupted by functionalisation of the central phenyl
ring. Zinc(II) is d10 and is more flexible in its coordination geo-
metry. This may account for the higher activity of 12 compared
to 11, which is more similar to the metal-free chelating unit
10.
The photophysical properties of the different BODIPY-AMD
derivatives were studied in PBS at room temperature. The data
are collected in Table 3. All compounds exhibit two absorption
bands characteristic of the BODIPY signature, which consists
Scheme 5 Synthesis of Bodipy-AMD3100 analogues.
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of the S0–S1 feature placed near 525 nm and the S0–S2 one
located near 380 nm, both readily assigned to spin-allowed
π–π* transitions. It is important to note that no aggregation
can be observed in PBS, which is mainly characterised by a
broadening of the absorption band as well as a dual absorp-
tion. The ε (λ) values of the Ni(II) and Zn(II)-AMD3100-BODIPY
11 and 12, are relatively high, ranging from 30 200 to 53 900
M−1 cm−1, those of free ligand 10 is a little lower (16 500 M−1
cm−1).
As an example, Fig. 3 exhibits the absorption, emission and
excitation spectra of compound 12 (see ESI† for all spectra).
The ΦF value of the AMD3100-BODIPY 10 is relatively low,
mainly because of the presence of several amine functions and
a flexible linker between the BODIPY and the AMD3100 part
(“loose bold effect”). Complexation of the Bodipy-AMD3100
analogue with Zn2+ (which naturally occurs when injecting
AMD3100 in vivo), resulted in a consequent enhancement of
the fluorescence, yielding to a quantum yield of 27% and a
brightness of 8200 M−1 cm−1, which is sufficient for at least in
vitro fluorescence imaging.34 Concerning the nickel complex
11, the fluorescence is still relatively low (Φ = 7%). Further
investigations would be needed to explain this phenomena,
which may be due to a paramagnetic character of NiII. Never-
theless, the brightness of the compound (almost 4000 M−1
cm−1) is sufficient for biological applications.
Introduction of a precursor for radiofluorination
Fluorine-18 has gained prominence in PET imaging in the
last decades due to its widespread availability, relatively low
cost of production and its optimal nuclear and chemical pro-
perties, i.e. low positron energy (635 keV), high abundance,
and relatively long half-life (109.7 min) when compared to
11C.35 Nevertheless with a half-life of 109.7 min, the synthesis
of labelled imaging agents needs to be rapid and efficient.
The B–F bond is one of the strongest bonds known, Ting
et al. developed a pinacol phenylboronate diester able to react
with F− in a single, rapid and high-yielding step at pH 4–7 in
aqueous solvents and at temperatures that are unlikely to
denature biomolecules.36 Inspired by this work, the pinacol
phenylboronate diester PET precursor was coupled to the
functionalised compounds 6 and 8 (Scheme 6).
Starting from a commercially available product, 4-(4,4,5,5-
tetramethyl-1,3-2-dioxaborolan-2-yl)benzoic acid, an acti-
vated ester 13 of the pinacol phenylboronate diester is syn-
thesised by reaction with N,N′-disuccinimidyl carbonate and
triethylamine in a 56% yield. Nucleophilic attack of 6 and 8
gives the resulting AMD3100 analogues 14 and 15 that consti-
tute two precursors for 18F radiolabelling. It has to be noted
that 15 was synthesised starting from compound 8 and not
by metallation of 14, because the pinacol boronate inter-
mediate was subject to hydrolysis during the metallation
step.
Fluoride treatment was performed on 14 to validate our
concept. Following a previous reported protocol,35 14 was dis-
solved in a small volume of deuterated methanol and an
aqueous solution of KHF2 (3.3 eq.) was added. The solution
turned immediately cloudy and further deuterated methanol
was added to dilute the solution. The reaction mixture was
stirred for 30 min at room temperature and the reaction was
followed by 11B and 19F NMR. The 11B signal was shifted from
31.6 ppm to 0.4 ppm and appeared as a quadruplet due to the
coupling between boron and fluorine. In the 19F NMR, the con-
Table 3 Photophysical properties of the BODIPY derivatives in PBS at
298 K
Compound
λabs
(nm)
λem
(nm)
ε
(M−1 cm−1) Φa
Brightnessb
(M−1 cm−1)
10 525 539 16 452 5 822
11 524 540 53 872 7 3771
12 524 540 30 167 27 8145
a The quantum yields, ΦF, were measured at 298 K, using rhodamine
6G (ΦF = 0.78 in water, λexc = 488 nm).
b Brightness = Φ × ε.
Fig. 3 Absorption (plain line), emission (large dashed line) and excitation (small dashed line) spectra of compound 11.
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sumption of KHF2 was evidenced by the disappearance of the
signal at −170 ppm and the presence of a signal at
−142.7 ppm, characteristic of a –BF3. Fluorination was also
confirmed by mass spectrometry. This experiment confirms
the high reactivity of the pinacol phenylboronate derivatives
and their potential as precursors for the synthesis of 18F
radiopharmaceuticals.
Conclusion
A series of novel CXCR4 antagonists have been synthesised in
this work and it has been demonstrated that functionalisation
of the central bridging phenyl group in AMD3100 can be
carried out without significant loss in the affinity for the
CXCR4 receptor. The compounds have been characterised as
sub-µM antagonists in a series of assays demonstrating
effective binding to the receptor in vitro. They have then been
modified for imaging applications via addition of a prosthetic
group for radiofluorination or a fluorescent dye molecule to
delineate the route to application. This design separates out
the targeting and imaging components of the molecule, which
is in contrast to the previously described complexes of
AMD3100 with radiometals. The modular approach is advan-
tageous in tuning for different modalities and optimum recep-
tor ‘on’ and ‘off’ binding rates. There is also the potential for
multimodal imaging to allow evaluation of the compounds by
a range of imaging techniques to more precisely characterise
the interactions from a cellular level up to in vivo studies. The
next steps for this study are to select the optimal candidates,
optimise the radiolabelling conditions and carry out prelimi-
nary in vivo studies. In addition, the affinity towards CXCR7 of
the novel compounds is under evaluation to determine the
binding profile with this important and related chemokine
receptor target.
Experimental section
Synthetic procedures
General information. Additional experimental details, data
for compounds 1–16 (NMR, MS spectra and HPLC chromato-
grams) are given in ESI.†
Material. TriBocCyclam was generously donated by CheMatech
and all other chemicals were purchased from Acros and
Aldrich and were used without further purification. Organic
solvents were removed under reduced pressure using rotary
evaporator. Water was removed by lyophilisation.
Methyl-2,5-dimethylbenzoate (1). A mixture of 2,5-dimethyl-
benzoic acid (10.0 g, 66.6 mmol), sulphuric acid (14 mL,
13.3 mmol), and methanol (27 mL) was heated at reflux for
4 h. The mixture was poured into water (250 mL) and extracted
with ethyl acetate (2 × 200 mL). The pooled organics were
washed with saturated sodium bicarbonate (2 × 50 mL) and
brine (50 mL), dried over MgSO4, and concentrated in vacuo to
give 1 (10.1 g, 92%) as a colorless oil. 1H NMR (300 MHz,
CDCl3, 300 K): δ = 7.70 (d,
4J (H,H) = 1.7 Hz, 1H; CH), 7.18 (dd,
3J (H,H) = 7.9 Hz, 4J (H,H) = 1.4 Hz, 1H; CH), 7.10 (d, 3J (H,H) =
7.9 Hz, 1H; CH), 3.86 (s, 3H; OCH3), 2.53 (s, 3H; CH3),
2.32 ppm (s, 3H; CH3);
13C{1H} NMR (75 MHz, CDCl3, 300 K):
δ = 168.4 (CvO), 137.2 (Car), 135.4 (Car), 132.9 (CHar), 131.8
Scheme 6 Synthesis of AMD3100 pinacol phenyl boronate analogues as PET precursors and AMD3100 trifluoroborate.
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(CHar), 131.2 (CHar), 129.6 (Car), 51.9 (OCH3), 21.4 (CH3),
20.9 ppm (CH3); ESI-MS: m/z: 165.31 [M + H]
+.
Methyl-2,5-bis(bromomethyl)benzoate (2). To a solution of
1 (10.1 g, 61.6 mmol) in carbon tetrachloride (300 mL) were
added N-bromosuccinimide (23.0 g, 129.3 mmol) and benzoyl
peroxide (1.0 g, 4.1 mmol). The reaction mixture was heated at
reflux for 4 h. The resulting suspension was filtered, and the
residue was washed with chloroform (3 × 150 mL). The pooled
organics were concentrated in vacuo to give a mixture of
product and succinimide as determined by 1H NMR. The
mixture was dissolved in dichloromethane (600 mL) and
washed with water (3 × 150 mL). The dichloromethane phase
was dried over MgSO4 and concentrated in vacuo, and the
resulting residue was purified by reverse phase flash chromato-
graphy on C18. After evaporation of acetonitrile, the aqueous
solution was freeze dried to give 2 (13.9 g, 70%) as a white
solid. 1H NMR (500 MHz, CDCl3, 300 K): δ = 8.00 (d,
4J (H,H) =
1.8 Hz, 1H; CH), 7.53 (dd, 3J (H,H) = 7.8 Hz, 4J (H,H) = 1.8 Hz,
1H; CH), 7.46 (d, 3J (H,H) = 7.8 Hz, 1H; CH), 4.94 (s, 2H; CH2),
4.49 (s, 2H; CH2), 3.98 ppm (s, 3H; OCH3);
13C{1H} NMR
(75 MHz, CDCl3, 300 K): δ = 166.6 (CvO), 139.6 (Car), 138.5,
133.2 (CHar), 132.5, 132.0, 129.7 (Car), 52.6 (OCH3), 32.0
(CH2), 31.0 ppm; ESI-MS: m/z: 322.54 [M + H]
+.
AMD3100 Boc-ester (3). To a solution of tris-tert-butyl-
1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate (2.00 g,
3.98 mmol) in acetonitrile (20 mL) was added K2CO3 (1.38 g,
9.99 mmol) and compound 2 (0.63 g, 1.99 mmol). The reaction
mixture was heated at 40 °C overnight. After cooling, the solu-
tion was filtered on celite. The solvent was evaporated and the
resulting oil was taken up in 200 mL of diethylether, washed
with 2 × 50 mL of water, dried over MgSO4 and concentrated
in vacuo. The resulting residue was purified by flash chromato-
graphy (A: CH2Cl2, B: CH3OH, B 35%) to give 3 (1.89 g, 82%) as
a white foam. m.p. 89 ± 1 °C; 1H NMR (300 MHz, CDCl3,
300 K): δ = 7.66 (s, 1H; CH), 7.43 (d, 3J (H,H) = 7.7 Hz, 1H; CH),
7.31 (d, 3J (H,H) = 7.7 Hz, 1H, CH), 3.85 (s, 3H; OCH3), 3.81
(s, 2H; CH2Ph), 3.51 (s, 2H; CH2Ph), 3.45–3.14 (m, 23H),
2.67–2.52 (m, 4H), 2.45–2.28 (m, 4H), 1.94–1.77 (m, 4H; CH2β),
1.70–1.61 (m, 4H; CH2β), 1.50–1.24 ppm (m, 54H; CH3);
13C{1H} NMR (125 MHz, DMSO, 343 K): δ = 167.4 (CvO), 154.5
(*2), 154.4, 154.3 (*2), 154.2, 138.1 (Car), 137.5 (Car), 131.3
(Car), 130.3 (CHar), 129.7 (CHar), 129.6 (CHar), 78.4, 78.3,
78.2, 78.1, 78.0 (*2), 57.8, 56.2, 52.7, 52.5, 51.3, 51.1, 46.7, 46.6,
46.5(*3), 46.2, 46.0, 45.9 (*2), 45.8, 45.7, 45.5, 45.4, 27.8 (*12)
(CH3), 27.7 (*3) (CH3), 27.6 (*3) (CH3), 25.9 (*2) (CH2β), 25.6
pm (*2) (CH2β); ESI-MS: m/z: 1183.76 [M + Na]+, 1199.73
[M + K]+; HRMS (ESI): m/z calcd for C60H104N8O14 + Na
+:
1183.7571, found 1183.7564; elemental analysis calcd (%) for
C60H104N8O14: C 62.04, H 9.02, N 9.65; found: C 61.62, H 8.98,
N 9.55; HPLC: tr = 8.13 min, purity 98%.
AMD3100 Boc-ethylenediamine (4). Compound 3 (1.89 g,
1.63 mmol) was dissolved in distilled ethylenediamine
(6.5 mL). The mixture was stirred at 40 °C for 7 days. The
mixture was concentrated by evaporation and the resulting oil
was taken up in acetone (200 mL). After filtration, the pooled
organics were concentrated in vacuo to give a yellow foam.
The resulting residue was purified by flash chromatography on
silica gel (A: CH2Cl2, B: CH3OH, B 15%) to furnish 4 (0.77 g,
40%) as a white foam. m.p. 98 ± 1 °C; 1H NMR (500 MHz,
CDCl3, 324 K): δ = 8.17 (br.s, 1H; NHCvO), 7.49 (s, 1H; CH),
7.25 (d, 3J (H,H) = 7.3 Hz, 1H; CH), 7.20 (d, 3J (H,H) = 7.6 Hz,
1H; CH), 3.64 (s, 2H, CH2Ph), 3.50 (s, 2H, CH2Ph), 3.46 (q,
3J (H,H) = 6.0 Hz, 2H; CH2NHCvO), 3.40–3.16 (m, 24H), 2.93
(t, 3J (H,H) = 6.0 Hz, 2H; CH2NH2), 2.66 (t,
3J (H,H) = 6.5 Hz,
2H), 2.60–2.52 (m, 2H), 2.46 (t, 3J (H,H) = 6.5 Hz, 2H), 2.40
(t, 3J (H,H) = 5.7 Hz, 2H), 2.10 (s, 2H), 1.89–1.77 (m, 4H; CH2β),
1.71–1.61 (m, 4H; CH2β), 1.44–1.39 (m, 36H; CH3),
1.37–1.24 ppm (m, 18H; CH3);
13C{1H} NMR (125 MHz, CDCl3,
324 K): δ = 169.9 (CvO), 156.1, 156.0, 155.9 (*2), 155.7 (*2),
138.7 (Car), 137.4 (Car), 135.1 (Car), 131.2 (CHar), 130.5 (CHar),
129.3 (CHar), 80.0, 79.9 (*2), 79.8 (*2), 79.7, 59.6 (CH2), 58.0,
53.5, 52.5, 52.4, 52.1, 51.1, 50.9, 48.1 (*2), 48.0, 47.5, 47.3 (*2),
46.9, 46.5, 43.1 (*2), 42.1 (*2), 28.9 (*3) (CH3), 28.8 (*9) (CH3),
28.7 (*3) (CH3), 28.6 (*3) (CH3), 27.2 (*2) (CH2β), 26.1 ppm (*2)
(CH2β); ESI-MS: m/z: 1189.82 [M + H]+; HRMS (ESI): m/z calcd
for C61H108N10O13 + H
+: 1189.8170, found 1189.8212; elemen-
tal analysis calcd (%) for C61H108N10O13: C 61.59, H 9.15,
N 11.77; found C 61.17, H 9.43, N 11.51; HPLC: tr = 8.48 min,
purity 96%.
AMD3100-ester (5). A solution of 3 M HCl (3.0 mL) was
added to 3 (100.0 mg, 0.08 mmol) and the reaction mixture
was stirred for one hour. The resulting product was left one
night at room temperature. The acid was evaporated in vacuo
giving 5 + 6HCl +10H2O. (60.7 mg, yield = 73%) as a white
foam. 1H NMR (300 MHz, D2O, 300 K): δ = 8.32 (d,
4J (H,H) =
1.8 Hz, 1H), 7.88 (dd, 3J (H,H) = 7.8 Hz, 4J (H,H) = 1.8 Hz, 1H),
7.76 (d, 3J (H,H) = 7.8 Hz, 1H), 4.46 (br.s, 2H), 3.98 (s, 3H;
OMe), 3.92–3.81 (m, 2H), 3.76–3.53 (m, 17H), 3.49–3.28 (m,
15H), 2.29–2.12 ppm (m, 8H); 13C{1H} NMR (75 MHz, D2O,
300 K): δ = 168.1, 135.9, 134.9, 134.2, 133.4, 131.2, 131.0, 48.2,
47.9, 45.5, 44.8, 42.1, 41.6, 41.5, 40.8, 40.7, 38.44, 38.38, 38.0,
37.2, 36.8, 19.1 (CH2β), 19.0, 18.5, 17.9 ppm; HRMS (ESI): m/z
calcd for C30H56N8O2 + H
+: 561.4599, found 561.4573; elemen-
tal analysis calcd (%) for C30H56N8O2 + 10H2O + 6HCl: C 37.54,
H 8.61, N 11.68; found C 37.82, H 8.05, N 11.65; HPLC:
tr = 5.53 min, purity 97%.
AMD3100-ethylenediamine (6). Compound 4 (0.47 g,
0.40 mmol) was dissolved in a solution of 3 M HCl (10 mL).
The mixture was stirred overnight at room temperature. The
mixture was evaporated, taken up in acetone (50 mL) and then
stirred overnight. The precipitate was filtered, washed with
acetone and ether and finally dried in vacuo. The compound 6
+ 9HCl + 5H2O was obtained as a white solid (400 mg, yield =
100%). 1H NMR (300 MHz, D2O, 300 K): δ = 7.93–7.91 (s, 1H),
7.81–7.74 (m, 2H), 4.51 (s, 2H; CH2Ph), 4.29 (s, 2H; CH2Ph),
3.82–3.78 (m, 2H), 3.67–3.34 (m, 32H), 3.18–3.14 (m, 2H),
2.27–2.16 ppm (m, 8H; CH2β); 13C{1H} NMR (75 MHz, D2O,
300 K): δ = 171.0 (CvO), 135.7 (CHar), 134.5 (CHar), 134.4
(CHar), 133.4 (Car), 131.6 (Car), 130.2 (Car), 58.1, 57.5, 48.4,
47.9, 47.8, 45.6, 45.3, 45.0, 42.1, 41.8, 41.7, 41.2, 41.0, 38.9,
38.7, 38.5, 38.1, 37.8, 37.7, 37.6, 19.3 (CH2β), 19.2 (CH2β), 18.8
(CH2β), 18.5 ppm (CH2β); HRMS (ESI): m/z calcd for
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C31H60N10O + H
+: 589.5024, found 589.5034; elemental ana-
lysis calcd (%) for C31H61N10O + 9HCl + 5H2O: C 36.97, H 7.91,
N 13.91; found C 37.13, H 8.06, N 14.33.
Few drops of NaOH (16 mol L−1) were added on compound
6 + 9HCl + 5H2O in order to obtain a viscous solution and
chloroform (100 mL) was added quickly. The two layers were
separated and the organic layer was dried over magnesium
sulfate. After evaporation of the solvent, 6 + 9.5H2O (276 mg,
yield = 91%) was obtained as a light yellow oil. 1H NMR
(300 MHz, CDCl3, 300 K): δ = 8.64 (t,
3J (H,H) = 5.4 Hz, 1H;
NHCvO), 7.41 (d, 3J (H,H) = 7.8 Hz, 1H), 7.37 (d, 4J (H,H) =
1.7 Hz, 1H), 7.12 (dd, 3J (H,H) = 7.8 Hz, 4J (H,H) = 1.7 Hz, 1H),
3.51 (s, 2H; CH2Ph), 3.37 (s, 2H; CH2Ph), 3.32 (q,
3J (H,H) =
5.9 Hz, 2H; CH2NHCvO), 2.76 (t,
3J (H,H) = 6.2 Hz, 2H;
CH2NH2), 2.71–2.19 (m, 40H), 1.72 (quint,
3J (H,H) = 5.5 Hz,
2H; CH2β), 1.63 (quint, 3J (H,H) = 5.5 Hz, 2H; CH2β),
1.55–1.45 ppm (m, 4H; CH2β); 13C{1H} NMR (75 MHz, D2O,
300 K): δ = 170.5 (CvO), 137.9 (Car), 137.6 (Car), 135.7 (Car),
130.6 (CHar), 130.4 (CHar), 128.0 (CHar), 57.9 (CH2Ph), 55.8
(CH2Ph), 54.6, 54.2, 53.3, 53.2, 50.9, 50.5, 49.3, 49.1, 48.7, 48.6,
48.5, 48.3, 48.2, 47.8, 47.7, 47.3, 43.1, 41.9, 28.6 (CH2β), 28.4
(CH2β), 26.5 (CH2β), 26.1 ppm (CH2β); elemental analysis calcd
(%) for C31H61N10O + 9.5H2O: C 48.99, H 10.48, N 18.43; found
C 49.00, H 10.57, N 18.33; HPLC: tr = 5.36 min, purity 99%.
Ni2AMD3100-ester (7). 0.60 mL (0.06 mmol) of a titrated
solution of Ni(NO3)2, 6H2O (c = 0.106 mol L
−1) in water were
added to a solution of 5 (17.3 mg, 0.03 mmol) in a 3 mL
mixture of MeOH–H2O (9 : 1). The reaction was stirred at 50 °C
overnight. After completion, reverse phase C8 semi-preparative
HPLC (A: H2O) was performed to furnish 7 (3.7 mg,
18%) as a light orange foam. HRMS (ESI): m/z calcd for
C30H54N8Ni2O2 − 2H2+: 337.1533, found 337.1529; HPLC: tr =
5.88 min, purity 95%.
Ni2AMD3100-ethylenediamine (8). 15.0 mL (1.59 mmol) of a
titrated solution of Ni(NO3)2, 6H2O (c = 0.106 mol.L
−1) in water
were added to a solution of 6 + 9.5H2O (568 mg, 0.79 mmol) in
a 110 mL mixture of MeOH–H2O (9 : 1). The reaction was
stirred at 50 °C overnight. After completion, reverse phase C18
flash chromatography (A: H2O) was performed to furnish 8 +
4NO3 + 7H2O (332 mg, 39%) as a light orange foam. UV-Vis
(PBS), λ (nm): 460; HRMS (ESI): m/z calcd for C31H58N10Ni2O −
2H2+: 351.1746, found 351.1740; elemental analysis calcd (%)
for C31H58N10Ni2O + 4NO3 + 9.5H2O: C 34.59, H 6.56, N 18.22;
found C 34.24, H 6.30, N 18.88; HPLC: tr = 5.77 min, purity 88%.
Bodipy-NHS-ester (9).30 54 mg of N-hydroxysuccinimide
(0.48 mmol), 58 mg of dimethylaminopyridine (DMAP)
(0.48 mmol) and 92 mg of 1-(3-dimethylaminopropyl)-3-ethyl-
carbodiimide hydrochloride (EDCI) (0.48 mmol) were added to
a solution of 4,4-difluoro-8-(4-carboxyphenyl-)1,3,5,7-tetra-
methyl-2,6-diethyl-4-bora-3a,4a-diaza-s-indacene (100 mg,
0.24 mmol) in CH2Cl2 (50 mL). The reaction was stirred at
35 °C. After complete activation of the acid function (2 h) fol-
lowed by TLC, the mixture was washed with 2 × 10 mL of
water, the organic phase was dried over MgSO4 and the solvent
was evaporated to give a red oil. The crude product was puri-
fied by chromatography on silica gel (AcOEt–Hexane 50 : 50).
Upon concentration of the pure fraction, recrystallisation in a
mixture of dichloromethane and hexane gave 9 as a red solid
(88 mg, yield = 70%). 1H NMR (300 MHz, CDCl3, 300 K): δ =
8.23 (d, 3J (H,H) = 8.3 Hz, 2H; CHarBod), 7.47 (d,
3J (H,H) =
8.3 Hz, 2H; CHarBod), 2.92 (bs, 4H; CH2CvO), 2.51 (s, 6H;
CH3), 2.27 (q,
3J (H,H) = 7.5 Hz, 4H; CH2CH3), 1.25 (s, 6H;
CH3), 0.96 ppm (t, 6H,
3J (H,H) = 7.5 Hz; CH2CH3);
13C{1H}
NMR (75 MHz, CDCl3, 300 K): δ = 169.2 (*2) (NCvO), 161.4
(CO2), 154.6 (*2) (Cpyrrole), 143.0 (CarBod), 138.7 (CBod), 138.0
(*2) (Cpyrrole), 137.7 (*2) (Cpyrrole), 133.3 (*2) (CHarBod), 131.2
(*2) (Cpyrrole), 129.3 (*2) (CHarBod), 125.6 (CarBod), 25.7 (*2)
(CH2CvO), 17.3 (*2) (CH2CH3), 14.6 (*2) (CH2CH3), 12.7 (*2)
(CH3), 12.1 ppm (*2);
11B{1H} NMR (192.5 MHz, CDCl3, 300 K):
δ = 0.79 ppm (t, 1J (B,F) = 33.1 Hz); ESI-MS: m/z = 544.21
[M + Na]+; UV-Vis (CH3CN), λ (nm) (ε, M
−1 cm−1): 525 (73 000),
492 (sh, 23 200), 378 (7940); elemental analysis calcd (%) for
C28H30BF2N3O4: C 68.50, H 6.67, N 6.39; found C 68.78,
H 6.87, N 5.95.
AMD3100-bodipy (10). Diisopropylethylamine (172 μL,
1.04 mmol) was added to a solution of 6 (408 mg, 0.69 mmol)
in acetonitrile (40 mL). A solution of bodipy 9 (694 mg,
0.69 mmol) in acetonitrile (10 mL) was then added and the
mixture was stirred at room temperature during 6 h, until total
consumption of the starting materials was observed by TLC.
Solvent was evaporated, and the resulting red oil was purified
by column chromatography on silica gel (eluent: CH2Cl2–
EtOH–NH4OH 20 : 60 : 20). Precipitation from CH2Cl2–hexane
gave the desired compound 10 as a red solid (446 mg, yield =
65%) Mp: >200 °C; 1H NMR (300 MHz, CDCl3, 300 K): δ =
9.80–9.67 (bs, 1H), 8.62–8.49 (bs, 1H), 8.12 (d, 3J (H,H) =
8.2 Hz, 2H), 7.55 (d, 3J (H,H) = 7.7 Hz, 1H), 7.43 (s, 1H), 7.33
(d, 3J (H,H) = 8.2 Hz, 2H), 7.20 (d, 3J (H,H) = 7.7 Hz, 1H),
3.73–3.46 (m, 12H), 2.79–2.31 (m, 37H), 2.26 (q, 4H, 3J (H,H) =
7.5 Hz; CH2CH3), 1.92–1.52 (m, 8H), 1.32–1.24 (m, 9H),
0.94 ppm (t, 3J (H,H) = 7.5 Hz, 6H; CH2CH3);
13C{1H} NMR
(75 MHz, CDCl3, 300 K): δ = 173.0 (NHCvO), 166.6, 154.3 (*2)
(Cpyrrole), 139.8 (Car), 139.3 (CarBod), 139.2 (CBod), 138.3 (*2)
(Cpyrrole), 138.2 (Car), 136.1, 134.5 (CarBod), 133.2 (*2) (Cpyrrole),
131.5 (CHar), 130.6 (*2) (Cpyrrole), 130.5 (CHar), 128.8 (*2)
(CHarBod), 128.3 (*2), 127.2 (CHar), 58.3 (CH2), 55.2, 54.9, 54.6,
54.2, 53.8, 53.2, 51.3, 51.1, 49.9, 49.4 (*2), 48.8, 48.6, 48.5, 48.4,
48.1, 47.1, 42.8, 39.7, 28.7 (CH2β), 28.6, 26.6, 26.2, 17.2 (*2)
(CH2CH3), 14.8 (*2) (CH2CH3), 12.7 (*2) (CH3), 12.0 ppm (*2);
11B{1H} NMR (96 MHz, CDCl3, 300 K): δ = 0.76 ppm (t,
1J (B,F) = 33.6 Hz); ESI-MS: m/z = 995.7 [M + H]+, 1021.7
[M + Na]+, 1033.7 [M + K]+; HRMS (ESI): m/z calcd for
C55H85BF2N12O2 + H
+: 995.7062, found 995.7012.
Ni2AMD3100-bodipy (11). 3.1 mg of NiCl2 (0.023 mmol) was
added to a solution of 10.4 mg of compound 10 (0.012 mmol)
in 6 mL of methanol. The mixture was stirred at 50 °C for 2 h.
After evaporation, compound 11 was obtained as a red solid
(14.2 mg, yield = 95%). ESI-MS: m/z = 555.27 [M − 2H − 4Cl]2+;
HRMS (ESI): m/z calcd for C55H85BCl4F2N12Ni2O2 − 2H −
4Cl2+: 555.2740, found 555.2699.
Zn2AMD3100-bodipy (12). 4.7 mg of Zn(OAc)2, 2H2O
(0.021 mmol) was added to a solution of 9.5 mg of compound
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10 (0.011 mmol) in 6 mL of methanol. The mixture was
stirred at 50 °C for 2 h. After evaporation, compound 12 was
obtained as a red solid (27.7 mg, yield = 97%). ESI-MS:
m/z = 592.28 [M − H − 3(OAc)]2+; HRMS (ESI): m/z calcd for
C63H97BF2N12O10Zn2 − H − 3(OAc)2+: 592.2783, found
592.2780.
Pinacol phenylboronate activate ester (13). Triethylamine
(340 µL, 2.43 mmol) and N,N′-disuccinimidyl carbonate
(310 mg, 1.21 mmol) were added to a solution of 4-(4,4,5,5-
tetramethyl-1,3-2-dioxaborolan-2-yl)benzoic acid (200 mg,
0.81 mmol) in acetonitrile (20 mL). The reaction mixture was
stirred at room temperature for 5 h. The solvent was evapor-
ated in vacuo with a bath temperature lower than 35 °C. The
resulting product was dissolved in dichloromethane and
washed with a saturated solution of sodium bicarbonate. After
drying over magnesium sulfate, the organic layer was evapor-
ated in vacuo with a low temperature bath >35 °C. Chromato-
graphy on silica gel (A: Pentane, B: EtOAc, B 50%) gave 13
(0.157 g, 56%) as a white powder. 1H NMR (300 MHz, CDCl3,
300 K): δ = 8.09 (d, 3J (H,H) = 8.1 Hz, 2H; CHarBpinacol), 7.90 (d,
3J (H,H) = 8.1 Hz, 2H; CHarNHS), 2.86 (s, 4H; CH2 NHS),
1.33 ppm (s, 12H; CH3);
13C{1H} NMR (75 MHz, CDCl3, 300 K):
δ = 169.4 (*2) (CCvO NHS), 162.1 (CCvO), 135.1 (Cpinacol),
129.6 (*4) (CH), 127.3 (CNHS), 84.6 (*2) (CMe2), 25.9 (*2) (CH2),
25.0 ppm (*4) (CH3); HRMS (ESI): m/z calcd for C17H20BNO6 +
Na+: 368.1279, found 368.1274.
AMD3100-pinacol phenylboronate (14). 6 (26 mg,
0.04 mmol) was dissolved in a mixture of acetonitrile (600 µL)
and DMF (20 µL), triethylamine (77 µL) was then added. The
solution was stirred at room temperature for 10 min and 13
(15 mg, 0.04 mmol) was added to the reaction. After one night
stirring at 40 °C, the solvent was evaporated under a nitrogen
flux to give 14 which still contains traces of DMF and was
directly used without any further purification step. 1H NMR
(500 MHz, CDCl3, 500 K): δ = 9.79–9.63 (bs, 1H; NH), 8.77–8.65
(bs, 1H; NH), 8.07 (dd, 3J (H,H) = 5.2 Hz, 4J (H,H) = 1.5 Hz,
2H), 7.75 (d, 3J (H,H) = 8.1 Hz, 1H), 7.72–7.65 (m, 1H), 7.63 (d,
3J (H,H) = 8.1 Hz, 1H), 6.63 (dd, 3J (H,H) = 5.1 Hz, 4J (H,H) =
1.5 Hz, 2H), 3.70–3.31 (m, 7H), 2.90–2.85 (m, 7H), 2.73–2.20
(m, 35H), 1.79–1.52 (m, 6H), 1.19 ppm (s, 12H); 11B (160 MHz,
CDCl3, 300 K): δ = 31.6 ppm; ESI-MS: m/z = 819.6 [M + H]
+;
MALDI-TOF: m/z = 819.63 [M + H]+.
Ni2AMD3100-pinacol phenylboronate (15). 8 (20 mg,
0.02 mmol) was dissolved in DMF (3 mL) and triethylamine
(25 µL) was added. The solution was stirred at room tempera-
ture for 10 min and 13 (8 mg, 0.02 mmol) was added to the
reaction. After one night stirring at 40 °C, the solvent was
evaporated in vacuo with a bath temperature lower than 35 °C
to give 15. MALDI-TOF: m/z = 931.36 [M − 3H]+.
AMD3100-phenyltrifluoroboronate (16). 14 (0.04 mmol) was
dissolved in methanol-d4 (150 µL) and a solution of KHF2 in
D2O (35 µL, c = 4 M) was added. The solution immediately
turned blurry and 1 mL of methanol-d4 was added. The
mixture was stirred for 30 min and NMR was recorded on the
crude product. 1H NMR (500 MHz, CD3OD, 500 K): δ = 8.08 (d,
3J (H,H) = 7.5 Hz, 2H), 7.72–7.69 (m, 1H), 7.61–7.57 (m, 1H),
7.44 (bs, 1H), 6.87 (d, 3J (H,H) = 6.9 Hz, 2H), 3.80–3.61 (m, 6H),
3.23–3.15 (m, 7H), 3.14–3.03 (m, 7H), 2.99–2.87 (m, 10H),
2.76–2.54 (m, 12H), 2.02–1.76 ppm (m, 6H); 11B (160 MHz,
CD3OD, 300 K): δ = 0.34 ppm (q,
1J (B,F) = 11.9 Hz);
19F (202 MHz, CD3OD, 300 K): δ = −142.7 ppm; ESI-MS: m/z =
759.5 [M − H]−.
Chemokine-induced calcium signalling assay
Ca2+ mobilisation assays were performed by the use of a fluoro-
metric imaging plate reader (FLIPR) (Molecular Devices,
Sunnyvale, USA) as described previously.26 Briefly, U87.CXCR4-
and U87.CCR5-transfected cells were loaded with the fluo-
rescent calcium indicator Fluo-3 acetoxymethyl (Molecular
Probes, Leiden, The Netherlands) in the appropriate culture
medium for 45 min at 37 °C, after which the cells were washed
three times in Hanks balanced salt solution buffer containing
20 mM HEPES and 0.2% bovine serum albumin (pH 7.4). The
cells were then incubated in the dark at 37 °C for 15 min with
the compounds. Changes in intracellular calcium concen-
tration upon addition of CXCL-12 (SDF-1), the specific ligand
for CXCR4, were simultaneously measured in all 96 wells in a
black-wall microtiter plate and in real time with the FLIPR.
The data were expressed as fluorescence units versus time and
were analysed using the FLIPR Control Software (Molecular
Devices) and IC50 values were calculated using GraphPad
Prism 4.0 software (San Diego, CA).
Anti-viral assays
Anti-HIV activity and cytotoxicity measurements in MT-4 cells
were based on the viability of cells that had been infected or
not infected with the CXCR4-using (X4) HIV-1 strain NL4.3
and exposed to various concentrations of the test compound.
After the MT-4 cells were allowed to proliferate for 5 days, the
number of viable cells was quantified by a tetrazolium-based
colorimetric method as described by Pauwels et al.27,37
Flow cell cytometry anti-CXCR4 antibody competition studies
Cell culture. Human leukaemia T cell lymphoblasts (Jurkat)
were obtained from MRL (University of Hull, UK). These cells
were cultured in RPMI 1640 medium treated with sterile fil-
tered fetal bovine serum (FBS) (10%) and penicillin and strep-
tomycin (100 units per 5 mL) antibiotics. The cells cultures
were maintained at 37 °C in a humidified, CO2 (5%) controlled
atmosphere with subculturing done every 2–3 days as
appropriate.
General procedure for binding assay with 12G-5 conjugated to
phycoerythrin
Phycoerythrin (PE)-conjugated mouse monoclonal anti-human
CXCR-4 and Mouse IgG2A isotype control-PE were purchased
from R&D systems Europe, Abingdon, UK.
Cells are harvested at about 75% confluency, centrifuged,
resuspended in 10 mL PBS and centrifuged again. Cells are
kept on ice to prevent receptor internalisation. Cells are resus-
pended in 1.0 mL of PBS/0.25% BSA/0.01 M NaN3 and viable
cells are counted using trypan-blue exclusion test. Cells at a
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density of 1–2 × 105 cells were aliquoted into polypropylene
FACS tubes and preincubated with 20 μM of the compound
(10 μL in 18.2 mΩ water) for one hour at 4 °C. A high concen-
tration of compound was used to ensure saturation of the
receptors. Thereafter, cells were washed with 1 mL of the
buffer (PBS/0.25% BSA/0.01 M NaN3) to remove the excess of
compound that did not bind to the cells’ receptors. Cells were
then incubated with the 12G-5 mAb conjugated to phycoery-
thrin for a further 60 min. The cells were washed with 1 mL of
the buffer and put in suspension in 300 μL of the buffer. Nega-
tive control was performed using the same protocol without
the preincubation step. The binding of our compound was
analysed by flow cytometry on a FACScan flow cytometer (BD
Biosciences Europe, Erembodegem, Belgium) using the follow-
ing FL channel FL-2 575/26 nm (PE/PI).
The potency of compounds is reported as a concentration
required to inhibit a specified amount (%) of the mABs. The
Mean Fluorescent Intensity (MFI) was used as a measure of
binding and a quantitative way of calculating the inhibition
percentage of mAb.
% mAb inhibition ¼ 100


MFI cells with compoundMFI negative control
MFI positive controlMFI negative control

 100

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